The Topical Shift: Transforming Atopic Dermatitis Treatment in Primary Care - Episode 7
Beyond Steroids: Clinical Trial Results on the Next Generation Agents for Atopic Dermatitis
nonsteroidal topicals including roflumilast (next-generation PDE4 inhibitor), ruxolitinib (JAK1/2 inhibitor), and tapinarof (aryl hydrocarbon receptor agonist) offer significant improvements in efficacy and tolerability compared with older agents like crisaborole, with clinical trial data showing 30% to 50% of patients achieving complete or near-complete clearance.
Video content above is prompted by the following:
Roflumilast represents a significant advancement in PDE4 inhibitor therapy for atopic dermatitis, offering 25 to 300 times greater potency than crisaborole. Approved for patients 6 years and older, this once-daily cream provides superior patient adherence compared with twice-daily crisaborole applications. The elegant cream formulation feels moisturizing rather than greasy like crisaborole’s ointment base, addressing common tolerability issues that limit treatment adherence in atopic dermatitis management.
Ruxolitinib cream, a JAK1/2 inhibitor approved for ages 12 and up, demonstrates exceptional efficacy in treating mild to moderate atopic dermatitis. Clinical trials show this twice-daily topical outperforms triamcinolone in head-to-head comparisons, achieving clear or almost-clear skin in over 50% of patients within 8 weeks. The drug’s unique homeostatic mechanism prevents immediate disease rebound upon discontinuation, with patients maintaining remission for several months—a distinctive advantage over traditional corticosteroids.
Tapinarof introduces an innovative aryl hydrocarbon receptor agonist mechanism, approved for patients 2 years and older as a once-daily cream. While slower-acting than other nonsteroidal options, tapinarof achieves mid-40% clear or almost-clear rates at 8 weeks with excellent itch control. The medication’s unique benefit includes sustained remission periods after achieving clearance, though practitioners should monitor for folliculitis—an acne-like eruption that resolves upon temporary treatment discontinuation.
